INFLAMMATORY IMMUNE COMPONENTS IN THE RETINA, MAJOR CAUSE OF THE WET MACULAR DEGENERATION (AMD).
Las Vegas, NV 8/04/2008 12:30 PM GMT (TransWorldNews)
SCPI will present evidence that the inflammatory process found in AMD is due to a combination of retinal antibodies and the immunosuppressive hormone (ectopic) cortisol immune components not found in normal retinae.
Our evidence would also show that the lesions associated with the wet macular degeneration, are occurring only after the main retinal immune barrier, the mineral zinc, had been overcame.
Zinc’s many activities in the retina, and the whole body, are well known, what is less known is it is a strong anti-cortisol/cortisol modulating agent (Zinc acutely and temporarily inhibits adrenal cortisol secretion in humans. A preliminary report, Brandao Neto et al Biol Trace Elem. Res Jan 1990: 24(1):83-9
The AMD is associated with aging, a high cortisol condition and perhaps is not a coincidence that the target of hypercortisolism in aging, is the hippocampus, the brain memory’s computer, but also the area with the highest concentration of Zinc. A preliminary but solid conclusion is that the treatment of AMD should consist in the use of anti-inflammatory cortisol modulators and reconstructive stem cell therapy in the retina plus the treatment with cortisol modulators of aging itself. (See article enclosed from the American College of Clinical Gerontology)
The SCPI approach (patent pending) to AMD consists in “the Product” and the way of administering it via the “Transsclera” technology (see SCPI’s release about “Transsclera” December 26th, 2007)
“The Product” consists in a small vial containing stem cells originating from the placental amniotic membrane, similar in action with the human embryonic cells, but minus the controversy, neurotrophic factors and a cortisol modulating compound. The Product is administered under the lower lid, where a proprietary procedure would be used that would permit it to rapidly cross the sclera, the retinal pigment epithelium (RPE), Bruch’s membrane and land on the first target, the photoreceptor area. There they would eventually differentiate in cones and rods (with practical applications in the retinitis pigmentosa (RP) and related conditions, Usher’s, Stargardt’s, LCA then would spill further in other areas, including the Müller’s dormant stem cells and hopefully reach the macula, where they would eventually reconstruct the cones. Their potential effects on the sub-retinal blood leakage is a matter of speculation.
While the scenario above looks complex, it should be known that they all could be carried out in accordance with existing protocols.
Towards this goal SCPI is looking for a Joint Venture (JV) partner where SCPI would provide the intellectual property (IP) and the partner would provide the facilities, to carry out preclinical studies in view of an eventual Orphan Drug IND, outside the US.
P.S. The next news release will be titled:
The statins or rather the SuperStatins ™ would dominate the world of medicine today and tomorrow, NOT as cholesterol lowering drugs, but as cortisol modulators.
Contact:
Alfred T. Sapse MD (r)
Tel. (702) 383-5893
Fax ((702) 733-9505
e-mail: draflredtsapse@yahoo.com
web: www.stemcellpharmainc.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
StemCell Pharma, Inc
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
